This content is machine translated Onco-Training St. Gallen News on metastatic colorectal cancer Metastatic colorectal cancer was the focus of an afternoon symposium in St. Gallen. Significant progress has been made in the field of colorectal cancer therapy in recent years, but this…
View Post 4 min This content is machine translated Metastatic colorectal cancer Which first-line therapy for patients with wild-type RAS? At this year’s ESMO Congress in Madrid, treatment options for metastatic colorectal cancer were also discussed. Is there an optimal strategy for patients with a wild-type RAS mutation, and would…
View Post 2 min This content is machine translated German-speaking European School of Oncology in St. Gallen The pros and cons of antiangiogenic therapy in first-line treatment. At a DESO advanced training course in St. Gallen, Prof. Volker Heinemann, MD, Munich, and Prof. Werner Scheithauer, MD, Vienna, led a discussion on the use of first-line antiangiogenic therapies.…
View Post 6 min This content is machine translated Interview at ASCO GI on new data from the OPUS study. “We are a good step closer to personalized therapy in mCRC” In the treatment of metastatic colorectal cancer, there were new results on subgroup analyses of the OPUS trial at this year’s ASCO GI in San Francisco. As previously shown in…
View Post 4 min This content is machine translated Treatment of metastatic colorectal carcinoma. Patients with RAS wild type benefit in overall survival New data on first-line treatment of metastatic colorectal cancer were presented at the ASCO GI in San Francisco. The post-hoc analyses consistently confirm that RAS mutation status is an important…
